Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drug
Biotech
Ramaswamy-backed Ambros launches with $125M to develop pain med
Ambros is using the money to fund a phase 3 trial of Abiogen's neridronate for Complex Regional Pain Syndrome type 1.
Angus Liu
Dec 16, 2025 1:32pm
Lilly lands next-gen pain asset in $1B SiteOne acquisition
May 27, 2025 11:30am
Lexicon feels the pain as non-opioid data underwhelm investors
Mar 3, 2025 9:52am
Tris shows its opioid alternative is less likely to be abused
Jan 28, 2025 10:53am
Tris' opioid alternative reduces post-surgery pain in phase 3
Jan 22, 2025 8:30am
Vertex's pain prospect underwhelms versus placebo, sinking stock
Dec 19, 2024 7:41am
